Phase II Preview For Roche's Dalcetrapib May Give CETP Inhibition A Boost
This article was originally published in The Pink Sheet Daily
Executive Summary
European Society of Cardiology Congress abstract for small study suggests Roche's dalcetrapib is safe and works on plaque burden.
You may also be interested in...
Merck CEO To Street: Watch For Short-term Adaptability, Long-Term Innovation
Newly named chairman, Merck’s CEO Ken Frazier, cites several – smallish – launches, flexibility, especially in the face of setbacks, and business development, and ongoing focus on innovation as priorities in 2012 that will lead to long-term sustainability.
Simcere Teams Up Again With Bristol-Myers For Co-Development In China
After signing a deal in deal in November 2010 for a MET-VEGFR-2 inhibitor, Simcere and BMS switch gears for a CETP inhibitor.
Simcere Teams Up Again With Bristol-Myers For Co-Development In China
After signing a deal in deal in November 2010 for a MET-VEGFR-2 inhibitor, Simcere and BMS switch gears for a CETP inhibitor.